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Background:  Breast cancer presents itself in a variety of histologic types, and the two 
most common types are invasive ductal carcinoma (IDC) and invasive lobular carcinoma 
(ILC). Based on comparative genomic hybridization (CGH) analyses, ILC is more 
closely related to low grade IDC than it is to intermediate and high grade IDC. Results 
from the BIG 1-98 trial demonstrate that post-menopausal women who are affected with 
estrogen receptor positive (ER+) ILC or luminal B (high grade) IDC experience a greater 
magnitude of benefit when they are treated with the aromatase inhibitor (AI) letrozole 
compared to treatment with the antiestrogen tamoxifen. To contrast, it has been found in 
the same trial that women affected with luminal A (low grade) IDC experience more 
benefit when treated with tamoxifen when compared to letrozole. It is therefore 
imperative to accurately distinguish low grade IDC from ILC considering their varying 
responses to adjuvant treatment. Despite genetic evidence suggesting a close relationship 
between ILC and low grade IDC, a clinically relevant gene set underlying a tumor’s 
biologic responsiveness to letrozole likely exists. The goal of this study is to use 
microgenomics to identify a clinically relevant candidate gene set that would discriminate 
between ILC and low grade IDC rather than relying solely on histomorphology and/or 
immunohistochemistry for the pathologic diagnosis, especially when conventional tests 
are conflicting. 
Methods:  Using 247 de-identified human breast carcinoma biopsies collected under 
standardized, stringent conditions, total RNA was extracted from carcinoma cells 
procured by laser capture microdissection to perform microarray analyses of 
approximately 22,000 genes to identify expression signatures associated with breast 
cancer characteristics.  Of the 247 LCM-procured samples, 14 were ER+ ILC, 9 were 
ER+ low grade IDC, and 43 were ER+ high grade IDC. The other 181 samples were 
either ER- or of another cancer type other than ILC and IDC. Candidate genes were 
selected by identifying those that were differentially expressed between ILC and low 
grade IDC (luminal A) and at the same time, had similar expression levels between ILC 
and high grade IDC (luminal B).  qPCR analyses of whole tissue samples were then 
utilized to validate the selected gene set.  
Results:  Comparison of microarray data from hormone receptor positive tumors yielded 
299 probes that were differentially expressed (p<0.01) between ILC and low grade IDC 
(luminal A), and 99 of these probes were not differentially expressed (p>0.01) between 
ILC and high grade IDC (luminal B). 11 of these 99 genes were initially chosen for 
further investigation by performing qPCR on whole tissue samples from 21 ILC, 19 low 
grade IDC and 19 high grade IDC tumors.  Our initial analysis revealed expression of the 
gene coding for heparin-binding EGF like growth factor (HBEGF) and collapsin response 
mediator protein 1 (CRMP1) may be potential markers for differentiating between ILC 





Overview of Breast Cancer 
Data accumulated in the SEER Database and in the long-term records of the 
American Cancer Society indicate that one in eight women will present with an invasive 
breast carcinoma at some point in her life. An estimated 232,340 new cases of breast 
cancer are expected to be reported in 2013 in the United States and more than 39,000 
women are predicted to die from this disease. Although the death rates from breast cancer 
have been decreasing, the incidence rates have been increasing since 1975 (1). 
Postmenopausal women are at a higher risk of developing breast cancer compared to 
premenopausal women (2).  
 
Pathology 
When a breast tumor is excised from a patient, it is sent to pathology for 
diagnosis.  Pathologic diagnosis for invasive carcinoma includes, but is not limited to, 
histologic type, histologic grade and estrogen receptor, progesterone receptor and HER2 
status.  The results provided by pathology guide patient management for selection of 
appropriate adjuvant therapy (3).  
The most common histologic type of invasive breast carcinoma is invasive ductal 
carcinoma (IDC), no special type.  IDC accounts for 70-75% of all invasive breast 
carcinomas.  The second most common histologic type is invasive lobular carcinoma  
(ILC), which accounts for 10% of all invasive breast carcinomas (4). The distinction 
between IDC and ILC is determined on hematoxylin and eosin stain (H&E), where IDC 
characteristically infiltrates as cohesive solid nests and tubules, and ILC characteristically 
infiltrates as single cells in single file. The differing appearance between these two 
histologic types is due to the presence or absence of E-Cadherin which is a membrane 
adhesion molecule (5). IDC expresses functioning E-Cadherin at its cell membrane 
surface allowing for adhesion among tumor cells resulting in the ability to form cohesive 
strucures such as tubules, whereas ILC lacks functional E-Cadherin and therefore exists 
as single cells infiltrating through stroma. Occasionally invasive carcinoma on H&E 
section can show variable histologic features with areas of the tumor demonstrating 
single cells in single file and other areas of the tumor demonstrating cohesive nests and 
tubule formation.  Adjunct immunohistochemical studies using antibodies to E-Cadherin 
can be used to support the histologic diagnosis (6).   
Typically, a lack of E-Cadherin immunostaining supports the diagnosis of ILC 
and the presence of membranous staining with E-Cadherin supports the diagnosis of IDC 
(3).  Although helpful in the majority of cases, E-Cadherin immunohistochemistry can be 
positive in 5-15% of ILC cases and occasionally low grade carcinomas demonstrating 
ductal features on H&E can be negative for E-Cadherin, resulting in possible 
misclassification of the histologic type (6).  In the past, the distinction between ILC and 
IDC was not imperative for treatment purposes since IDC and ILC were treated the same, 
however with the recent results of the BIG 1-98 trial, discriminating between IDC and 
ILC will decide whether the patient will benefit more from Tamoxifen versus an 
aromatase inhibitor, which will be discussed further throughout this Thesis (25). As such, 
it is clinically imperative to be able to distinguish between ILC and IDC due to variable 






 The grading of a breast tumor is a clinically relevant prognostic factor that 
measures the degree of differentiation in the carcinoma. The Nottingham grading system 
considers three criteria: tubule formation, nuclear pleomorphism and mitotic counts (7). 
The scale ranges from 1 to 3 with Grade 1 carcinomas being well-differentiated and 
Grade 3 lesions appearing as poorly-differentiated. Patients exhibiting Grade 1 
carcinomas have the most favorable prognosis in regard to overall survival (OS) and 
disease free survival (DFS) while those patients with Grade 3 cancers have the poorest 
predicted outcomes (8). The study population consisted of de-identified patients 
exhibiting either IDC or ILC on which there are microarray expression data of 22,000 
genes using LCM-procured breast carcinoma cells (9, 10). Clinical features of this patient 
population were assessed to ensure they represent the population at large of breast 
cancers. We observed that there was a noticeable difference in patient survival, both OS 




Figure 1.  Challenges in diagnosing invasive lobular carcinoma versus invasive 
ductal carcinoma of the breast.  (A) Invasive carcinoma illustrating the formation of 
tubules (encircled). The same invasive carcinoma in (A) stains negatively for E-cadherin 
with the internal positive control shown (arrow) (B). (C) Invasive carcinoma showing 
infiltration as single cells (arrow) and in single file (*), which is E-Cadherin positive (D). 
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(Grade 3, n=85) carcinomas (Fig. 2). The risk of recurrence and survival are very 
different among the various grades which is extremely important considering that grading 
has been shown to be an independent predictor of survival and recurrence in invasive 
carcinomas (8). It should also be noted that there was a difference in DFS and OS of 
patients with Grade 1 IDC compared to ILC and properly distinguishing between the two 
may serve as a predictor of survival and an indicator of aggressiveness, which would be 





Conventional Biomarkers: ER, PR, and HER-2/neu 
 
Estrogen Receptor 
The estrogen receptor (ER) is a nuclear steroid hormone receptor protein whose 
presence, or lack thereof, is used as a prognostic factor as well as a predictive biomarker 
correlating with responses to endocrine therapies for advanced breast carcinomas (11, 
12). As a prognostic factor, it along with the progestin receptor (PR), serve as 
independent predictors of breast cancer survival (13) Currently, there are two widely 
acknowledged estrogen receptors, ERα and ERβ, and they have been found to be 
regularly expressed in different tissues in the body. ERα is expressed in the major female 
organs, (including the mammary gland), the hypothalamus, and bone while ERβ is 
expressed in the ovary, major male organs, and parts of the central nervous system (14). 
It is the ERα protein that is useful as a predictive factor in hormone treatment 
responsiveness, with ER+ invasive breast tumors displaying a more favorable response to 
adjuvant treatment with antiestrogens such as Tamoxifen than ER- carcinomas (15, 16). 
Beyond simply functioning as a predictive indicator, the ER in breast cancer has become 
a target for developing highly specialized endocrine therapies, including both 
antiestrogens and aromatase inhibitors, which will be discussed later.  
 
 












































































Figure 2.  Kaplan-Meier survival curves of patients with ILC and graded IDC 
among the population with microarray data.  (A) Disease Free Survival (DFS), (B) 





The progestin receptor (PR) is a nuclear steroid hormone receptor that is regulated 
by the ER (11, 12). The presence of PR in a tissue is thought to indicate an active ER in 
the same cells and thus can be used as a predictive factor for more accurate responses to 
endocrine therapies in ER+ breast tumors (11, 12, 17). Roughly 5% of breast carcinomas 
are ER-/PR+ but they often respond to hormone therapies (15, 16, 18). 
 
Sex-Hormone Receptor Analyses 
There are two major methods used in quantifying steroid receptor proteins: 
The first, the ligand-binding assay (LBA), which is also known as the multipoint 
titration assay (MTA), detects the presence of steroid receptors by using radiolabeled 
ligands (e.g.[3H]estradiol-17) that bind specifically to estrogen or progesterone 
receptors. This particular assay quantifies the concentration of receptor proteins, which is 
expressed as the specific binding capacity measured in femtomoles of radio-labeled 
ligand bound per milligram of cytosol protein (fmol/mg). Using the LBA, the dissociation 
constant (Kd value) also may be estimated, which measures the binding affinity of the 
labeled ligand to its receptor. Using this type of assay, the cutoff value indicating ER+ or 
PR+ in tissues has been set at ≥ 10 fmol/mg by the FDA (11, 12). However, this assay is 
not specific to ERα and may also be used to detect ERβ with ligands exhibiting 
estrogenic activities (19). The second major method involves the utilization of antibodies 
to detect epitopes that are specific to each of the receptor proteins. Because the antibodies 
are unique to each receptor protein, the presence of ERα and ERβ may be determined 
separately. Two assays that use this method are the enzyme immunoassay (EIA) (20) and 
the enzyme-linked immunoassay (ELISA)(11, 12). Because the EIA and ELISA 
techniques specifically detect a domain on the receptor protein, their results are not 
affected by endogenous or exogenous steroid hormones. Both EIA and ELISA utilize a 
spectrophotometer to measure the intensity of the labeled colored product, which allows 
accurate quantification of the receptor proteins.  
IHC analysis (21) also use antibodies specific to the receptor proteins; however 
the assay only provides semi-quantitative results (22). However, a problem with IHC is 
that the interpretation of the degree of staining by the labeled antibodies is subjective 
(highly operator dependent) due to variable stain intensities due to unstandardized 
conditions that have only been corrected recently (22). Thus the results of this assay are 
only semi-quantative, and were not used in the studies described in this thesis. Since the 
ER and PR proteins arise from the translation of their cognate mRNA molecules, real-
time reverse transcription polymerase chain reaction (RT-PCR) is a reliable technique for 
measuring gene expression. This assay determines the level of mRNA for the genes 
coding for ER (ESR1) and PR (PGR) in a sample and compares this to a control gene, 
producing a relative expression level (23). RT-PCR is able to specifically look for the 









Therapeutic Treatments for ER+ Invasive Carcinomas 
The complex of female sex hormone or its mimic with the estrogen receptor 
protein is required to initiate a response in both normal and carcinoma cells. One of the 
responses of the ER signaling pathway is the production of the progestin receptor protein 
Thus, the hormone receptor status of normal breast tissue cells and breast cancer cells is 
physiologically important because estrogens and progestins stimulate differentiation and 
proliferation in both types of breast tissue. Therefore, if a breast cancer biopsy is ER+, its 
growth may be controlled by several therapeutic approaches following the surgical 
removal of the primary carcinoma. One of the therapeutic approaches involves blocking 
the ability of the ER protein to bind native estrogen molecules in a cell, thus inhibiting its 
action. This type of treatment utilizes manmade drugs called antiestrogens (also called 
SERMs, Selective Estrogen Receptor Modulators), such as the drug Tamoxifen (15, 16, 
24). 
 A second class of therapeutic agents reduces the amount of estrogen produced 
and circulating in a female patient’s body by inhibiting the enzymatic conversion of 
androgen building blocks into estrogens. The enzyme promoting this conversion of a 
weak male sex hormone into an estrogen in adipose tissues is called an aromatase, and 
the manmade drugs that inhibit the enzymatic activity are called aromatase inhibitors 
(AI). An example of a currently used AI is Letrozole (25). AIs apparently do not block 
the production of estrogens in the ovaries due to the high level of production and thus the 
second therapeutic approach appears to be most effective in post-menopausal women 
since their ovaries are no longer producing estrogen.  
Although AIs are most effective in post-menopausal breast cancer patients, it has 
been found that different types of invasive breast carcinomas have varied responses to 
Letrozole. For example, patients with low grade IDC (luminal A-like) exhibit a trend 
toward lower overall survival than women with ILC when these patients were treated 
with Letrozole (25). This suggests there is a molecular basis for the differences observed 
in the therapeutic responses of the two histologic types of breast carcinomas.  
 
HER-2/neu Oncoprotein 
HER-2/neu is a transmembrane glycoprotein that is a member of the human 
epidermal growth factor receptor (HER, or EGFR) family and was originally identified in 
neuroglioblastoma of rats, hence neu. The other members of the EGFR family are HER-
1, HER-3, and HER-4. HER-2 has no known ligand but acts by heterodimerizing with 
another member of the family and the heterodimer becomes active when the internal 
domain of the other dimer member is phosphorylated via tyrosine kinases (26).  
Overexpression of HER-2 oncoprotein in breast cancer appears to be associated with poor 
prognosis (27). Breast carcinomas with overexpression of HER-2 have been shown to 
have a poorer response to endocrine therapies than tumors with an expression level that is 
normal to non-cancer cells (28). The expression of the HER-2 protein has a clinical utility 
in that patients with carcinomas that overexpress it are more likely to respond to therapies 







HER-2/neu Oncoprotein Analyses 
 Since HER-2/neu oncoprotein has no known ligand, the manner in which the 
membrane bound biomarker may be determined utilizes antibody based assays in either 
EIA or ELISA formats (11, 12). Therefore, the quantified results represent HER-2/neu 
content in a breast cancer tissue biopsy, but not activity. The current assay for assessing 
HER-2/neu oncoprotein in tissue biopsies is by IHC (27). However, early studies utilized 
“home-brew” assays before standardization guidelines were recently issued by the 
College of American Pathologists (CAP) in association with the American Society of 
Clinical Oncologists (ASCO) (30). It should be noted that all values used in the studies 
reported in this thesis were quantified either by EIA or ELISA.  
 
Statement of Problem 
It is imperative to be able to properly distinguish between the two histologic 
types, Low Grade IDC and ILC, and we propose that a set of genomic markers exist 
within breast carcinoma cells that allow a molecular means of distinguishing them as an 
aid to the pathologist. Our hypothesis is that each of these histologic types of breast 
carcinoma, IDC and ILC, may be identified using a molecular signature reflecting a 
distinct pattern in the expression of certain genes. This set of genomics-based biomarkers 
will advance the pathologist’s ability to discern IDC from ILC when conventional 
pathologic parameters are conflicting. Discriminating between Grade 1 IDC and ILC 
would improve the ability to assess prognosis (i.e., risk of recurrence) as well as aid in 






II. RELATIONSHIP OF EXPRESSION OF CONVENTIONAL 
BIOMARKERS IN ILC COMPARED TO IDC 
 
 
Currently, ER PR and HER-2/neu protein quantities in breast carcinoma tissue 
biopsies serve as the principal biomarkers for assessing a patient’s risk of recurrence and 
as a predictor of therapeutic response. (11, 12). Therefore, data mining studies were 
performed using deidentified information in the comprehensive IRB-approved Database 
to ascertain whether expression of these protein biomarkers is related to the various 
histologic subtypes and the ability to distinguish ILC from Grade 1 IDC.  
 
Methods and Materials 
Estrogen Receptor and Progestin Receptor Levels  
  ER and PR protein levels were determined previously using either enzyme 
immunoassay (EIA) or radio-labeled ligand binding assay (LBA) (11, 12, 31) and the 
results were incorporated into the comprehensive, de-identified Database established by 
Dr. Wittliff. Briefly, both methods utilized chilled/frozen specimens that were sliced 
carefully with a scalpel on a Petri dish chilled on a frozen ice pack to maintain receptor 
integrity and then homogenized with a mass-to-buffer ratio of 100 mg wet weight of 
tissue per 1.0 ml of 40 mM Tris-HCl buffer, pH 7.4, containing 1.5 mM EDTA, 10% 
glycerol, 10 mM sodium molybdate, 10 mM monothioglycerol and 1 mM PMSF (12).  
Extracts were prepared by centrifugation at 100,000 x g for 30 min. 
A complete ligand binding assay was comprised of duplicates of six increasing 
concentrations of radiolabeled [3H-estradiol-17β] with and without unlabeled 
diethylstilbestrol in a titration format (12, 31).  Reactions were incubated overnight (12-
18 h) at 4˚C.  Unbound ligand was removed by addition of dextran-coated charcoal, 
incubated for 15 min, and then centrifuged at 3300 x g for 15 min at 4ºC.  Supernatant 
was removed and radioactivity was detected in a liquid scintillation counter. Specific 
ligand binding capacity, reflecting the receptor level, was expressed as fmol/mg cytosol 
protein while the resulting apparent dissociation constant (Kd value) determined by 
Scatchard analysis was expressed as M. 
Determination of ER and PR levels by EIA employed a kit formerly distributed 
by Abbott Laboratories (12, 31) and the results were incorporated into the 
comprehensive, de-identified Database.  This protocol utilized beads coated with Anti-ER 
monoclonal antibodies, which were incubated with the tissue extracts (12, 31).  Unbound 
materials were aspirated and washed, before the bead-associated receptor protein was 
incubated with anti-receptor antibodies conjugated with horseradish peroxidase.  Color 
was developed and measured with a spectrometer at a wavelength of 492 nm. The 
receptor level (mass) was expressed as fmol/mg cytosol protein. Thus each of the ER and 









Results and Discussion 
Relationships of Biomarker Protein Levels and Breast Cancer Subtypes  
The first investigation that was conducted related to the hypothesis was to 
determine if there was a relationship between the expression of the conventional breast 
cancer biomarkers and patient/cancer biopsy characteristics. This was accomplished by 
mining the IRB-approved comprehensive Database. After completing the evaluation of 
ER, PR, and HER-2/neu oncoprotein individually, assessment of the utility of combining 
expression of ER and PR protein was performed. As explained earlier, these analyses of 
sex hormone receptors are routinely performed as a pair by IHC (22). Although, triple 
negative breast cancer is the subject of many investigations because of the implication for 
aggressive disease which is difficult to treat (4, 16), the limited number of breast cancer 
tissue biopsies used in the current study with HER-2/neu results precluded examination in 
combination with other biomarkers. Furthermore, our genomic studies focused primarily 
on ER+ breast carcinomas.  
Examining data from ER+ tissue samples, no significant difference was found in 
the ER protein levels between ILC (n=90) and Grade 1 IDC (n=90). The median 
concentration in ILC using LBA and/or using EIA was 129 fmol/mg. The median protein 
concentration in Grade 1 IDC using LBA and/or EIA was 150 fmol/mg. When 
performing a Dunn’s multiple comparisons test, the only significant difference (p<0.05) 
in quantified protein concentrations was between Grade 2 IDC and Grade 3 IDC (Fig. 3). 
 
 
In PR+ tissue samples, there was no significant difference found in the progestin 
receptor protein levels between ILC (n=85) and Grade 1 IDC (n=78). The median 
concentration in ILC using LBA and/or EIA was 161 fmol/mg. The median protein 
concentration in Grade 1 IDC using LBA and/or EIA was 256 fmol/mg. However, it was 
found that progestin receptor protein levels were significantly lower (p<0.05) in Grade 3 
IDC (n=208) when compared respectively to Grade 1 IDC, Grade 2 IDC (n=235), and 


















































A similar type of analysis was performed using the HER-2 oncoprotein results 
from each of the breast cancer subtypes. The quantified levels of the HER-2/neu 
oncoprotein also showed no statistically significant difference (p<0.05) among any of the 
grades of IDC and ILC (Fig. 5). 
 
 
ER and PR protein levels in breast carcinoma biopsies are routinely analyzed as 
described earlier. To determine if their expression was different in the breast cancer 
























































































Figure 4. Quantified PR protein levels in different histologic types. 
 




grade compared to that in ILC (Fig. 3-5). When analyzing the entire patient population 
with associated clinical data (n=831), we found that patients presenting with ILC (n=97) 
and Grade 1 IDC (n=85) have similar expression of ER positivity at 88% and 93%, 
respectively, while only 44% of Grade 3 IDC (n=350) were positive for ER using 
established cut-off values (Table 1A). 
In regard to progestin receptor status, ILC (n=97) and Grade 1 IDC (n=85) 
exhibited similar expression of PR positivity at 84% and 79%, respectively, in the study 
population while only 55% of Grade 3 IDC (n=350) exhibited PR+ levels (Table 1A). 
Closer examination of the data revealed that 78.4% of the study population that presented 
with ILC (n=97) had ER+/PR+ status and 73.9% of Grade 1 IDC (n=73) biopsies were 
ER+/PR+. A much lower expression of ER+/PR+ status (36.8%) was observed for Grade 
3 (n=291) carcinomas (Table 1B). Low grade experiencing higher ER and PR positivity 
and high grade experiencing the opposite as well as ILC showing similar hormone 
receptor positivity as low grade IDC is consistent with existing literature (13, 32) 
Due to the similar protein expression levels and statuses, ER, PR, and HER-2/neu 







Negative - 59 (20%)
Postitive - 220 (74%) Positive - 192 (55%)
Negative - 12 (12%) Negative - 16 (16%) Negative - 6 (7%) Negative - 18 (21%)
ER-/PR- 1 (1.4%)
ER-/PR- 115 (39.5%)
Negative - 158 (45%)
Grade 3 IDC (n=350)
PR
Positive - 154 (44%)
Negative - 79 (26%)
ER
Negative - 196 (56%)
PRER
PR
Positive - 67 (79%)
Grade 2 IDC (n=299)
Positive - 240 (80%)
Positive - 79 (93%)





























Table 1. ER and PR Statuses among Entire Patient Population. (A) ER and PR statuses 
among varying histologic types. (B) ER/PR statuses among varying histologic types. 
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Relationships of Biomarker Gene Expression Levels and Breast Cancer Subtypes  
 In order for a biomarker protein to be synthesized in a cell, expression of the 
cognate gene must occur and there must be fidelity in the transcription of the gene and 
the translation of the mRNA. This occurs routinely in normal cells. However, the 
molecular basis of gene and protein expressions in carcinoma cells may be discordant 
because of errors at various steps in the process. Since the levels of the ER, PR and HER-
2 proteins in breast cancer tissue biopsies were not related to histologic subtypes, the 
expressions of the receptor genes were examined using results in the comprehensive 
Database. 
Expression of the genes that code for the estrogen (ESR1) and progestin (PGR) 
receptor proteins and the HER-2/neu (ERBB2) protein (Fig. 6) were ascertained by 
analyzing microarray data of breast carcinoma cells from 247 tissue biopsies (168 of 
those cancer specimens were either IDC or ILC) that were obtained via laser-capture 
microdissection (LCM) (9, 10) as will be discussed further in Chapter III.   
Examination of the microarray data clearly indicated that ESR1 expression was 
not significantly different (p<0.05) between Grade 1 IDC (n=13) and ILC (n=15). It is 
worth noting that the relative gene expression in Grade 3 IDC (n=85) was significantly 
lower (p<0.05) than all other tumor histologic types which supports previous evidence of 
a lower percentage of ER+ tumors being exhibited in Grade 3 IDC (Fig. 6A) (13).  
Using the same extensive Database, PGR expression also was not significantly 
different (p<0.05) in LCM procured breast carcinoma cells from Grade 1 IDC (n=13) 
compared to those from ILC (n=15). The gene expression in Grade 3 IDC (n=85) was 
significantly lower (p<0.05) than that of the other tumor histologic types which again 
supports previous reports that the lower percentage of PR+ tumors are Grade 3 IDC   
(Fig. 6B) (13). 
Using similar analyses for ERBB2, the relative expression levels of this gene 
were not significantly different (p<0.05) among any of the breast carcinoma subtypes 


















































































































































Figure 6. Relative gene expression levels from microarray data (N=168) of 






In summary, careful analyses of quantified results from the comprehensive 
Database indicated there were no significant differences between Grade 1 IDC and ILC 
with regard to expression of the biomarkers ER, PR, and HER-2 oncoprotein.  This was 
observed for the frequency distribution of positive/negative statuses, receptor protein 
concentration, and relative gene expression. Thus, neither the expression of the 
biomarkers proteins nor their genes serve as appropriate diagnostic tools for 
discriminating between Grade 1 IDC and ILC when conventional pathologic tests are 
conflicting. It is necessary to identify new biomarkers to accomplish this goal. This 
clinically relevant question was then approached using microgenomics to identify a gene 
signature that may be used to differentiate between these two histologic types in order to 











III. IDENTIFICATION AND VALIDATION OF POTENTIAL 
GENE SIGNATURES   BY COMPARING EXPRESSION IN 
ILC AND IDC 
 
 Methods and Materials  
Using an IRB-approved Database and Biorepository composed of de-identified 
specimens previously collected under stringent conditions (12) for clinical assays of 
estrogen (ER) and progestin receptors (PR), tissue sections of primary invasive ductal 
carcinomas obtained from 1988-1996 were examined using REMARK criteria (33). 
Patients were treated with the standard of care at the time of diagnosis. Tissue-based 
properties (e.g., pathology, grade, size, and tumor marker expression) and patient-related 
characteristics (e.g., age, race, smoking status, menopausal status, stage, and nodal status) 
were utilized to determine relationships between gene expression and clinical parameters. 
Carcinoma cells were procured from tissue sections of 247 frozen breast cancer 
tissue specimens using the PixCell IIe (Arcturus) laser capture microdissection (LCM) 
instrument and workstation using protocols established in our laboratory (cf (9, 10, 10). A 
retrospective analysis of gene expression was also performed on intact frozen tissues 
from 233 biopsies of invasive ductal carcinoma (Table 3).  Tissue sections utilized for 
these analyses contained a median of 60% breast carcinoma cells (range of 10-95%) and 
25% stromal cells (range of 5-65%). 
 
Gene Selection 
     Gene candidates for identifying a molecular signature were selected by mining the 
results from microarray analyses of LCM-procured carcinoma cells from 247 de-
identified human breast carcinoma biopsies. Of the 247 carcinoma specimens 
(disregarding ER/PR statuses), 16 were ILC, 13 were low grade IDC, 55 were 
intermediate grade IDC and 85 were high grade IDC (Fig. 7).  
 Initial analyses identified 1267 probes that were differentially expressed (p<0.01) 
between cell samples from patients with IDC compared to those with ILC, regardless of 
ER/PR status. Gene expression levels in breast carcinoma cells from patients with low 
grade IDC compared to those with ILC yielded 200 sequences that were differentially 
expressed (p<0.01). When comparing high grade IDC to ILC, 149 of these genes were 
not differentially expressed (Fig. 7). 
Similar analyses were performed using only the microarray results from patients 
with ER+/PR+ cancers (n=107). Gene expression levels in carcinoma cells from patients 
with low grade IDC compared to ILC yielded 299 probe sequences (p<0.01). 99 of these 
genes were not differentially expressed when comparing high grade IDC to ILC (p>0.01). 
15 genes were the same in the analysis of low grade IDC compared to ILC regardless of 
ER/PR status and in the same analysis with only ER/PR+ patient samples indicating that 
this gene set may serve as a panel of gene candidates.  Of the 15 probes sequences, 11 







RNA Isolation and qPCR Analysis 
  Total RNA from LCM-procured cells was isolated using PicoPure® 
(Arcturus/Life Technologies) kits, which are optimized for extracting RNA from cells 
procured by LCM (23, 34).  RNA in intact tissue sections, extracted with RNeasy® 
(Qiagen, Valencia, CA) kits, was analyzed prior to proceeding with LCM by utilization 
of the BioanalyzerTM instrument and reagents (Agilent Technologies, Palo Alto, CA), 
which estimates integrity of total RNA through analysis of the 18S and 28S rRNA 
profiles given by electrophoretic separation, and a RIN (RNA Integrity Number) which 
provides a numerical estimate of RNA integrity of the sample. Total RNA from either 
intact tissue sections or LCM-procured cells was reverse transcribed, and cDNA obtained 
was diluted 10-fold in 2 ng/μl polyinositol (Sigma) and used for the qPCR reactions (23, 
34). qPCR reactions were performed using a total volume of 10 μl, containing Power 
22,000 genes from 
microarray
15 genes common 
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Sybr® Green PCR Master Mix (Applied Biosystems), forward/reverse primers and 
cDNA obtained from the reverse transcription reaction. Primers were designed using 
Primer Express® 3.0 (Applied Biosystems). Relative gene expression analyses were 
performed using the ΔΔCt method using β-actin (ACTB) as a reference gene. Expression 
of genes was compared to those present in Universal Human Reference RNA (Stratagene, 
La Jolla, CA) in order to obtain a relative expression level of target gene produced. 
 
Statistical Analyses 
  T-tests and analysis of variance (ANOVA) were performed either in Microsoft® 
Excel or GraphPad Prism® Version 5 (GraphPad Software, La Jolla, CA).  Box and 
whisker plots and Kaplan-Meier survival curves were generated in GraphPad Prism® 
Version 5. Univariate and multivariate cox regressions were performed with SPSS® 
Statistics 20 (SPSS Inc., Chicago, IL) for correlations with disease-free (DFS) and overall 
survival (OS).   Survival calculations were performed using log2 transformations of 
relative gene expression data.  
 
Results and Discussion 
 
Relative Expression of Gene Candidates from Microarray Data 
 Expression profiling of cells using the microarray technique allows for high-
throughput genetic analysis, with over 20,000 genes per sample analyzed in our 
investigation. Breast carcinomas consist of a variety of cell types and in order to obtain a 
high purity of cancer cells, laser-capture microdissection (LCM) was used to procure the 
carcinoma cells. Although non-microdissected ILC and IDC lesions have been 
genetically profiled in previous studies (35), LCM-procured cells offer the best 
opportunity for analyzing specific cell types without running the risk of including normal 
epithelial, adipose, or endothelial breast cells (9, 10).  
 Although there is evidence that tumors of the same histologic type have similar 
gene expression profiles from microarray regardless of their ER status (36), we first 
investigated both ER+ cancers and carcinomas regardless of their receptor status when 
performing t-tests (p<0.05) to determine which genes were differentially expressed 
between Grade 1 IDC and ILC but similar between Grade 3 IDC and ILC. Initially, 15 
gene candidates were identified, but 3 of the genes were expressed sequence tags (ESTs) 
and a commercially available probe could not be designed for those ESTs (Fig. 7). Also, 
the design of a probe for one of the gene candidates was unsuccessful, thus only 11 gene 
candidates were selected for further evaluation.  
 Due to the parameters employed for the initial gene selection, each was 
statistically differentially expressed (p<0.01) among Grade 1 IDC and ILC and not 
differentially expressed (p>0.01) between Grade 3 IDC and ILC (Fig. 7.) The 11 genes 
that were chosen for validation by quantitative polymerase chain reaction (qPCR) were 
BRWD1, CAPSL, CHRNA7, CMTM7, CRMP1, FAM210A, GSKIP, HBEGF, HYMAI, 
PAPPA, and LRBA. Box and Whisker Plots of the gene expression levels of the breast 
carcinoma cell types are shown in Figure 8 which provides a visual of their expression 



















Validation of Gene Candidates by qPCR Analyses 
 After identifying gene candidates for developing a clinically relevant molecular 
signature, it was necessary to validate the microarray results using qPCR analyses. 
Although the qPCR assay does not permit analyses of the vast number of genes as 
accomplished by the microarray technique, it is more accurate. This is due to the fact that 
microarray uses a single probe to amplify a gene, whereby qPCR uses both forward and 
backward probes that are necessary for amplification. However, intact frozen tissue 
sections were used for qPCR analyses in these studies rather than LCM-procured cells. 
Thus there is a slightly increased possibility that gene expression of non-cancerous breast 
cells were being analyzed. This possibility is greatly reduced due to the fact that we 
selected breast carcinoma specimens with elevated carcinoma cell content as described 
earlier. Also, instead of the 247 LCM-procured specimens analyzed in the microarray, the 
qPCR validation was performed using 58 whole tissue sections. Each of the specimens 
studied was from postmenopausal patients with ER+ carcinomas: n=19 for Grade 1 IDC; 
n=18 for Grade 3 IDC; n=21 for ILC. 
 Following validation of the 11 gene candidates by qPCR (Table 2, Table 3,      
Fig. 9), two genes were found to be differentially expressed to a degree of statistical 
significance (p<0.05) (Table 3). The levels of the gene CRMP1, which is the collapsin 
response mediator protein 1, were overexpressed compared to that of the housekeeping 
gene, β-actin in ILC and but not in Grade 1 IDC (Fig. 9). From a previous report, CRMP1 
appears to be involved in the suppression of cancer invasion and metastasis in lung 
cancer cells (37). The levels of the second gene HBEGF, which codes for the heparin-
binding EGF-like growth factor, appear to be underexpressed compared that of β-actin in 
Grade 1 IDC and slightly overexpressed compared to the reference gene in ILC (Fig. 9). 
Overexpression of HBEGF has been found to promote breast metastasis and invasion 
specifically in ER- tumors (38), and to play a role in tumor aggressiveness in triple 





































Gene mean Grade 1 IDC mean ILC P value mean Grade 1 IDC mean ILC P value
BRWD1 0.425 -0.309 0.005 1.001 1.261 0.607
CAPSL 2.023 0.202 0.010 1.852 1.406 0.432
CHRNA7 -0.755 0.442 0.002 -1.234 -0.670 0.255
CMTM7 -1.443 0.212 0.007 -0.502 0.204 0.140
CRMP1 -0.331 1.074 0.009 -0.078 0.733 0.022
FAM210A 0.224 -0.328 0.005 -0.976 -1.030 0.787
GSKIP 0.378 -0.199 0.011 0.669 1.009 0.233
HBEGF -0.376 0.512 0.004 -0.533 0.059 0.036
HYMAI -0.840 0.281 0.008 -2.082 -1.583 0.524
PAPPA -0.200 0.431 0.008 -1.579 -1.138 0.159
LRBA 0.533 -0.237 0.004 1.689 2.096 0.375
Microarray Data qPCR Data
Table 3. T-test of microarray data and qPCR data comparing gene candidate 





















Pearson correlations were performed on the samples with which we had both 
qPCR and microarray data (n=29) to determine if the results of the two techniques 
correlated (Table 4). Only 4 of the 11 gene candidates (CAPSL, CMTM7, HBEGF, 
HYMAI) showed a statistically significant correlation (p<0.05) between the assay 
platforms, which is not unexpected considering the vastly different protocol formats. 
 
 
 Our preliminary results indicate that HBEGF and CRMP1 are differentially 
expressed in breast cancer subtypes. Interestingly, HBEGF was expressed to a 
significantly different degree between Grade 1 IDC and ILC using results from either 
microarray or qPCR (Fig. 8 & 9). Also expression levels appeared to be correlated 
between the two techniques. These initial results identify HBEGF expression as a 
potential marker differentiating between Grade 1 IDC and ILC.  HBEGF, a ligand for 
EGFR and other ErbB receptors, has been implicated in enhancing the malignant 
potential of a number of cancers, including breast cancer (38). Although the results from 
qPCR analyses also suggest CRMP1 expression as a potential marker for distinguishing 
breast cancer subtypes, additional carcinoma specimens are required to validate these 
findings. 
 As described earlier, we observed that there was a noticeable difference in both 
disease-free and overall survival of breast carcinoma patients in our study population 
when one compares those exhibiting low grade (Grade 1) compared to high grade (Grade 
3) carcinomas (Fig. 2). The risk of recurrence and survival are very different among the 
various grades which is extremely important considering that grading is known to be an 
independent predictor of survival and recurrence in invasive carcinomas (8). We also 
observed that there was a difference in DFS and OS of patients with Grade 1 IDC 
compared those with ILC (Fig. 2). Our preliminary findings clearly indicate that 
expression of HBEGF and CRMP1 in tissue biopsies may aid the pathologist in 













HBEGF 0.6981 < 0.0001
HYMAI 0.4594 0.0122
PAPPA - AJ420467 0.08267 0.6698
PAPPA - AI271743 0.1512 0.4337
LRBA -0.04324 0.8271
Pearson Correlation (n=29)
Table 4. Pearson Correlation comparing expression results from 






IV. SUMMARY AND CONCLUSION 
 
There are instances in which conventional pathologic tests to classify IDC and ILC 
are conflicting, and it is imperative to properly distinguish between these two types due 
to variable responses to endocrine treatments as well as differing prognoses. 
Conventional biomarkers such as ER, PR, and HER-2/neu offer little assistance in 
differentiation, in regard to both protein receptor status and gene expression. However, 
microgenomics may be of use in differentiating between the two most common types of 
breast cancer in women. Microarray analyses of LCM-procured cells have allowed us to 
examine the genomic profiles of specific tumor cells from 247 patients, and we have 
identified 11 genes candidate that could act as clinically relevant gene signatures. Gene 
expression levels retrieved from qPCR can be used to validate the candidate genes that 
were identified by microarray assays. 
Two genes, CRMP1 and HBEGF, were identified as gene candidates and validated by 
qPCR as significantly differentially expressed between Grade 1 IDC and ILC. These two 
genes therefore merit further investigation as potential clinically relevant gene signatures 
that would discriminate between invasive lobular and ductal breast carcinomas. Future 
plans are to expand the patient sample and collect more data from qPCR so that more 
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